Show simple item record

dc.contributor.authorBerrevoets, MAH
dc.contributor.authorKouijzer, IJE
dc.contributor.authorAarntzen, EHJG
dc.contributor.authorJanssen, MJR
dc.contributor.authorDe Geus-Oei, L-F
dc.contributor.authorWertheim, HFL
dc.contributor.authorKullberg, B-J
dc.contributor.authorOever, JT
dc.contributor.authorOyen, WJG
dc.contributor.authorBleeker-Rovers, CP
dc.date.accessioned2017-04-03T09:46:43Z
dc.date.issued2017-09
dc.identifier.citationJournal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017, 58 (9), pp. 1504 - 1510
dc.identifier.issn0161-5505
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/542
dc.identifier.eissn1535-5667
dc.identifier.doi10.2967/jnumed.117.191981
dc.description.abstractMetastatic infection is an important complication of Staphylococcus aureus bacteremia (SAB). Early diagnosis of metastatic infection is crucial, because specific treatment is required. However, metastatic infection can be asymptomatic and difficult to detect. In this study, we investigated the role of 18 F-FDG PET/CT in patients with SAB for detection of metastatic infection and its consequences for treatment and outcome. Methods: All patients with SAB at Radboud University Medical Center were included between January 2013 and April 2016. Clinical data and results of 18 F-FDG PET/CT and other imaging techniques, including echocardiography, were collected. Primary outcomes were newly diagnosed metastatic infection by 18 F-FDG PET/CT, subsequent treatment modifications, and patient outcome. Results: A total of 184 patients were included, and 18 F-FDG PET/CT was performed in 105 patients, of whom 99 had a high-risk bacteremia. 18 F-FDG PET/CT detected metastatic infectious foci in 73.7% of these high-risk patients. In 71.2% of patients with metastatic infection, no signs and symptoms suggesting metastatic complications were present before 18 F-FDG PET/CT was performed. 18 F-FDG PET/CT led to a total of 104 treatment modifications in 74 patients. Three-month mortality was higher in high-risk bacteremia patients without 18 F-FDG PET/CT performed than in those in whom 18 F-FDG PET/CT was performed (32.7% vs. 12.4%, P = 0.003). In multivariate analysis, 18 F-FDG PET/CT was the only factor independently associated with reduced mortality ( P = 0.005; odds ratio, 0.204; 95% confidence interval, 0.066-0.624). A higher comorbidity score was independently associated with increased mortality ( P = 0.003; odds ratio, 1.254; 95% confidence interval, 1.078-1.457). Conclusion: 18 F-FDG PET/CT is a valuable technique for early detection of metastatic infectious foci, often leading to treatment modification. Performing 18 F-FDG PET/CT is associated with significantly reduced 3-mo mortality.
dc.formatPrint-Electronic
dc.format.extent1504 - 1510
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectStaphylococcus aureus
dc.subjectBacteremia
dc.subjectStaphylococcal Infections
dc.subjectFluorodeoxyglucose F18
dc.subjectTreatment Outcome
dc.subjectRisk Factors
dc.subjectRetrospective Studies
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectYoung Adult
dc.subjectPositron Emission Tomography Computed Tomography
dc.title<sup>18</sup>F-FDG PET/CT Optimizes Treatment in <i>Staphylococcus Aureus</i> Bacteremia and Is Associated with Reduced Mortality.
dc.typeJournal Article
dcterms.dateAccepted2017-03-13
rioxxterms.versionofrecord10.2967/jnumed.117.191981
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of nuclear medicine : official publication, Society of Nuclear Medicine
pubs.issue9
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging
pubs.publication-statusPublished
pubs.volume58
pubs.embargo.termsNot known
icr.researchteamTranslational Molecular Imagingen_US
dc.contributor.icrauthorOyen, Willemen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record